The estimated Net Worth of Permanent Fund Corp Alaska is at least 257 千$ dollars as of 16 October 2020. Permanent Alaska owns over 235,000 units of Codiak BioSciences stock worth over 257,235$ and over the last 11 years Permanent sold CDAK stock worth over 0$.
Sign up
Permanent Alaska CDAK stock SEC Form 4 insiders trading
Permanent has made over 3 trades of the Codiak BioSciences stock since 2013, according to the Form 4 filled with the SEC. Most recently Permanent bought 235,000 units of CDAK stock worth 3,525,000$ on 16 October 2020.
The largest trade Permanent's ever made was buying 1,562,500 units of Codiak BioSciences stock on 31 July 2013 worth over 25,000,000$. On average, Permanent trades about 1,099,167 units every 878 days since 2013. As of 16 October 2020 Permanent still owns at least 4,512,895 units of Codiak BioSciences stock.
You can see the complete history of Permanent Alaska stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Permanent Alaska's mailing address?
Permanent's mailing address filed with the SEC is 801 WEST 10TH STREET, SUITE 302, JUNEAU, AK, 99801.
Insiders trading at Codiak BioSciences
Over the last 4 years, insiders at Codiak BioSciences have traded over 15,220$ worth of Codiak BioSciences stock and bought 11,821,475 units worth 20,798,957$ . The most active insiders traders include Steven Gillis、Venture Fund Viii, L.P.Arch...、Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of 19,158$. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth 326$.
What does Codiak BioSciences do?
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Codiak BioSciences's logo look like?
Complete history of Permanent Alaska stock trades at American Homes 4 Rent、Vir Biotechnology Inc、Codiak BioSciences
Codiak BioSciences executives and stock owners
Codiak BioSciences executives and other stock owners filed with the SEC include:
-
Dr. Douglas Edward Williams Ph.D.,
Pres, CEO & Director -
Dr. Sriram Sathyanarayanan Ph.D.,
Chief Scientific Officer -
Yalonda Howze,
Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. -
Dr. Benny Sorensen M.D., Ph.D.,
Member of Scientific Advisory Board & Consultant -
Dr. David J. Mauro M.D., Ph.D.,
Chief Medical Officer -
Dr. Benny Sorensen,
Member of Scientific Advisory Board & Consultant -
Richard Brudnick,
Chief Bus. Officer & Head of Corp. Strategy -
Nicole Barna,
Sr. VP of HR -
Christopher J. M. Taylor,
VP of Investor Relations & Corp. Communications -
Dr. Konstantin Konstantinov,
Chief Technology Officer -
Linda Cathavina Bain CPA,
CFO & Treasurer -
Arundathy N. Pandite,
Director -
Anne Virginie Eggimann,
Director -
Ventures Fund V General Par...,
-
Richard Brudnick,
See Remarks -
Venture Fund Viii, L.P.Arch...,
-
Charles L Cooney,
Director -
Kyriazi Theo Melas,
Director -
Briggs Morrison,
Director -
Eric S Lander,
Director -
Jason Haddock,
Director -
Karen Bernstein,
Director -
Steven Gillis,
Director -
Permanent Fund Corp Alaska,
-
Benny Sorensen,
See Remarks -
Nicole Barna,
See Remarks -
Jennifer J. Wheler,
Chief Medical Officer -
Ajay Verma,
See Remarks -
David J Mauro,
Chief Medical Officer -
Douglas E Williams,
President & CEO -
Konstantin Konstantinov,
Chief Technology Officer -
Linda Bain,
Chief Financial Officer -
Sriram Sathyanarayanan,
Chief Scientific Officer -
Yalonda Howze,
See Remarks